MedPath

Clinical Trial News

Navigating the $35 Billion Biosimilar Market: New Marketing Paradigms for Success

  • The biosimilar market is projected to reach $35 billion by 2020, presenting significant opportunities within the $169 billion biologics sector for companies that can effectively differentiate their products.
  • Marketing biosimilars presents a unique challenge: manufacturers must first establish similarity to gain physician trust, then differentiate their products through innovative delivery systems and value-added services.
  • With over 700 biosimilars currently in development, success requires extensive market education, strategic differentiation, and substantial investment in patient-centric solutions beyond competitive parity.

Ropeginterferon Alfa-2b Evaluated as Second-Line Therapy for High-Risk Essential Thrombocythemia in SURPASS-ET Trial

  • The SURPASS-ET trial is evaluating ropeginterferon alfa-2b as a second-line treatment for high-risk essential thrombocythemia (ET).
  • This Phase III trial compares ropeginterferon alfa-2b to anagrelide in patients resistant to or intolerant of hydroxyurea.
  • Ropeginterferon alfa-2b, a long-acting interferon, has shown a good safety profile in polycythemia vera and may offer a new option for ET patients.
  • The study assesses the safety, efficacy, tolerability, and pharmacokinetics of ropeginterferon alfa-2b, addressing an unmet need for effective ET therapies.

Ropeginterferon Alfa-2b (P1101) vs. Anagrelide in Essential Thrombocythemia Patients With Hydroxyurea Resistance or Intolerance

NCT04285086Active, Not RecruitingPhase 3
PharmaEssentia
Posted 8/25/2020

Topotecan Shows Significant Activity in Second-Line Treatment of Small-Cell Lung Cancer

  • Topotecan demonstrates notable efficacy in treating small-cell lung cancer (SCLC) patients who have previously undergone chemotherapy.
  • The study reveals a higher response rate among patients sensitive to prior chemotherapy, with an overall response rate of 37.8%.
  • Hematologic toxicity, particularly neutropenia, was the primary adverse effect, but it was generally manageable and short-lived.
  • The findings suggest that topotecan could be a valuable component in future combination chemotherapy regimens for SCLC.

Abemaciclib Shows Promise in ER+/HER2- Advanced Breast Cancer Treatment

• Abemaciclib, a CDK 4/6 inhibitor, presents a valuable therapeutic avenue for patients with ER+/HER2- advanced metastatic breast cancer, offering a continuous dosing schedule unlike other CDK 4/6 inhibitors. • Clinical trials demonstrate that abemaciclib provides similar clinical benefits to palbociclib and ribociclib in first- and second-line treatments, but with a distinct toxicity profile. • The ongoing MONARCH-E trial exploring abemaciclib in the adjuvant setting for high-risk, node-positive patients could significantly broaden its impact in early breast cancer treatment. • Biomarker research from studies like neoMONARCH may help identify tumors most responsive to abemaciclib, optimizing its use in personalized treatment strategies.

Landiolol Effectively Manages Post-Operative Supraventricular Tachycardia After Lung Resection

  • Landiolol, an ultra-short-acting β1-blocker, significantly reduced heart rate in patients experiencing post-operative supraventricular tachycardia after pulmonary resection.
  • The study demonstrated that continuous intravenous infusion of landiolol led to a reduction in heart rate from 135±24 bpm to 85±19 bpm (P<0.0001).
  • Conversion to normal sinus rhythm was observed in 56% of patients treated with landiolol, highlighting its potential in managing post-operative atrial fibrillation or flutter.
  • Landiolol was found to be safe and effective, with no detectable side effects on the circulatory or respiratory systems in the studied patient population.

Pre-Transplant MRD Positivity Linked to Poorer Survival in Acute Leukemia Patients

  • A study of 114 acute leukemia patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT) reveals that pre-transplant minimal residual disease (MRD) positivity is associated with worse outcomes.
  • Patients with MRD+ status before transplantation had significantly lower one-year overall survival (OS) and progression-free survival (PFS) rates compared to MRD- patients.
  • Multivariate analysis identified MRD positivity as an independent prognostic factor for overall survival, highlighting the need for improved pre-transplant MRD management strategies.
  • The research suggests focusing on more effective chemo regimens with targeted agents to achieve MRD- status before transplantation and better management of GvHD prophylaxis.

Naltrexone Shows Promise in Reducing Fatigue in Primary Sjögren’s Syndrome

  • A prospective, open-label study suggests low-dose naltrexone (LDN) may alleviate fatigue in patients with primary Sjögren’s syndrome (pSS).
  • The study observed a statistically significant reduction in fatigue scores, as measured by the Fatigue Severity Scale (FSS), following LDN treatment.
  • LDN was well-tolerated, with no serious adverse events reported, indicating a favorable safety profile for pSS patients.
  • These findings support further investigation of LDN as a potential therapeutic option for managing fatigue, a common and debilitating symptom of pSS.

Psychedelics Show Promise in Treating Anxiety and Depression in Cancer Patients

  • A review of five randomized, double-blind, placebo-controlled trials suggests psychedelics may offer a novel approach for treating anxiety and depression in cancer patients.
  • Studies showed significant reductions in anxiety and depression scores using various scales, with benefits potentially lasting for 6 to 12 months after only a few sessions.
  • The unique mechanism of action of psychedelics may provide relief for patients who do not respond well to traditional antidepressants, addressing a significant unmet need.
  • Despite promising results, the studies were small and had methodological limitations, including observed increases in blood pressure and heart rate.

PLEASE Trial Assesses Prolonged Antibiotic Treatment for Persistent Lyme Symptoms

  • The Persistent Lyme Empiric Antibiotic Study Europe (PLEASE) investigates optimal treatment for borreliosis-attributed persistent symptoms.
  • The study is a randomized, double-blind, placebo-controlled trial comparing short-term versus long-term antibiotic regimens.
  • Researchers aim to determine if prolonged antibiotic treatment improves patient outcomes compared to standard short-term therapy.
  • The trial includes patients with persistent pain, fatigue, and cognitive issues following Lyme disease, evaluating physical and mental health.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.